PDS Biotechnology Corp
PDS Biotechnology Corp (PDSB): 6 pipeline candidates · 1 upcoming catalyst · ~15 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
15.1 months
D/E 5.34 · 0% dilution
Lead: Phase 3
6 candidates
1 upcoming, next in ~959d
N/A
A transparent, data-derived signal for PDS Biotechnology Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$51.1M
Cash
$21.7M
Quarterly Burn
$4.4M
Runway
15.1 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| infectimune | — |
| pds0101 | Phase 3 |
| pds01adc | Phase 2 |
| pds0202 | Preclinical |
| versamune | — |
| versamune hpv | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
41
Total value held
$4.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,262,178 | $2.0M |
| geode capital management, llc | 660,228 | $399K |
| blackrock, inc. | 554,048 | $335K |
| caption management, llc | 319,100 | $193K |
| vanguard fiduciary trust co | 307,311 | $186K |
| renaissance technologies llc | 220,800 | $134K |
| inspirion wealth advisors, llc | 181,995 | $110K |
| armistice capital, llc | 173,605 | $105K |
| state street corp | 133,333 | $81K |
| wells fargo & company/mn | 110,500 | $67K |
Showing top 10 of 41 institutional holders of PDS Biotechnology Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PDS Biotechnology Corp's pipeline?
PDS Biotechnology Corp (PDSB) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PDS Biotechnology Corp's next catalyst?
PDS Biotechnology Corp's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-" — expected February 1, 2029.
What is PDS Biotechnology Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PDS Biotechnology Corp has approximately 15.1 months of cash runway.
What is PDS Biotechnology Corp's market capitalization?
PDS Biotechnology Corp's market capitalization is approximately $51.1M.
Who is the CEO of PDS Biotechnology Corp?
Dr. Frank K. Bedu-Addo Ph.D. is the chief executive officer of PDS Biotechnology Corp (PDSB).
Get the full picture on PDS Biotechnology Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.